Virax Biolabs Group Limited (VRAX)

$0.33 +0.02 (6.45%)
Market Cap 1.35M
Revenue (ttm) 10,000.00
Net Income (ttm) -6.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -60,600.00%
Debt to Equity Ratio 0.04
Volume 314,400
Avg Vol 6,382,224
Day's Range N/A - N/A
Shares Out 4.34M
Stochastic %K 22%
Beta 1.69
Analysts Strong Sell
Price Target $1.00

Company Profile

Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7788 7414
Address:
BioCity Glasgow, Bo’Ness Road Newhouse, Lanarkshire, United Kingdom
Tokoyama
Tokoyama Jan. 14 at 6:42 PM
$VRAX shares not being delisted and company positioning for sale. Thats why the 25m shares.
0 · Reply
Joshr1371
Joshr1371 Jan. 14 at 6:19 PM
$VRAX “This isn’t dilution — it’s preparation.”
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 14 at 6:18 PM
$VRAX loading
0 · Reply
Tokoyama
Tokoyama Jan. 14 at 6:13 PM
$VRAX company positioning for sale - thats why the 25m shares. Don’t sell.
0 · Reply
Tokoyama
Tokoyama Jan. 14 at 9:27 AM
$VRAX You also Bucky….2026 being bought, deal being prepped up, increased share count for deal.
1 · Reply
Tokoyama
Tokoyama Jan. 14 at 9:25 AM
$VRAX 25 m shares because being purchased in 2026. EOM
0 · Reply
ucla44life
ucla44life Jan. 12 at 4:46 PM
$VRAX
0 · Reply
Joshr1371
Joshr1371 Jan. 10 at 8:19 PM
$VRAX
0 · Reply
rombrento
rombrento Jan. 9 at 6:16 PM
$VRAX
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 9 at 5:18 PM
$VRAX
0 · Reply
Latest News on VRAX
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Dec 4, 2025, 4:05 PM EST - 5 weeks ago

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

Virax Biolabs Group Limited Announces $5 Million Private Placement

Dec 3, 2025, 1:53 PM EST - 6 weeks ago

Virax Biolabs Group Limited Announces $5 Million Private Placement

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Dec 3, 2025, 7:34 AM EST - 6 weeks ago

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Nov 3, 2025, 8:29 AM EST - 2 months ago

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Jul 29, 2025, 7:35 AM EDT - 6 months ago

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Jul 18, 2025, 4:15 PM EDT - 6 months ago

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Mar 31, 2025, 2:57 PM EDT - 10 months ago

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Mar 18, 2025, 7:30 AM EDT - 10 months ago

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Mar 13, 2025, 7:30 AM EDT - 10 months ago

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Mar 5, 2025, 7:30 AM EST - 11 months ago

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Feb 25, 2025, 7:00 AM EST - 11 months ago

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Jan 23, 2025, 3:35 PM EST - 1 year ago

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

COSM

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

Jan 13, 2025, 9:20 AM EST - 1 year ago

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

COSM

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Dec 17, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Dec 10, 2024, 7:30 AM EST - 1 year ago

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar

COSM

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

COSM

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Virax Biolabs to Participate at 7th European Congress of Immunology

Aug 29, 2024, 9:03 AM EDT - 1 year ago

Virax Biolabs to Participate at 7th European Congress of Immunology

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Aug 28, 2024, 2:18 PM EDT - 1 year ago

Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Aug 28, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Aug 23, 2024, 4:09 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Aug 21, 2024, 9:30 PM EDT - 1 year ago

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

Aug 21, 2024, 10:20 AM EDT - 1 year ago

Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits

COSM

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024

Virax Biolabs to Participate at ESCMID Global 2024

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Virax Biolabs to Participate at ESCMID Global 2024

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Dec 21, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Dec 14, 2023, 7:30 AM EST - 2 years ago

Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Sep 12, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Sep 1, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Jul 18, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

May 4, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Apr 19, 2023, 7:30 AM EDT - 2 years ago

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 10, 2023, 5:17 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 8, 2023, 8:55 AM EST - 3 years ago

Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Mar 7, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

Feb 7, 2023, 9:15 AM EST - 3 years ago

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

COSM

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

Feb 7, 2023, 8:30 AM EST - 3 years ago

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

COSM

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Feb 6, 2023, 4:05 PM EST - 3 years ago

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

Jan 4, 2023, 7:30 AM EST - 3 years ago

Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Dec 6, 2022, 7:30 AM EST - 3 years ago

COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Nov 15, 2022, 7:30 AM EST - 3 years ago

Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Nov 8, 2022, 4:30 PM EST - 3 years ago

Virax Biolabs Group Limited Announces Closing of $3.8 Million Private Placement

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Nov 4, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces $3.8 Million Private Placement

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Nov 3, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Oct 26, 2022, 7:30 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

Sep 22, 2022, 8:07 AM EDT - 3 years ago

Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

COSM

Tokoyama
Tokoyama Jan. 14 at 6:42 PM
$VRAX shares not being delisted and company positioning for sale. Thats why the 25m shares.
0 · Reply
Joshr1371
Joshr1371 Jan. 14 at 6:19 PM
$VRAX “This isn’t dilution — it’s preparation.”
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 14 at 6:18 PM
$VRAX loading
0 · Reply
Tokoyama
Tokoyama Jan. 14 at 6:13 PM
$VRAX company positioning for sale - thats why the 25m shares. Don’t sell.
0 · Reply
Tokoyama
Tokoyama Jan. 14 at 9:27 AM
$VRAX You also Bucky….2026 being bought, deal being prepped up, increased share count for deal.
1 · Reply
Tokoyama
Tokoyama Jan. 14 at 9:25 AM
$VRAX 25 m shares because being purchased in 2026. EOM
0 · Reply
ucla44life
ucla44life Jan. 12 at 4:46 PM
$VRAX
0 · Reply
Joshr1371
Joshr1371 Jan. 10 at 8:19 PM
$VRAX
0 · Reply
rombrento
rombrento Jan. 9 at 6:16 PM
$VRAX
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 9 at 5:18 PM
$VRAX
0 · Reply
ucla44life
ucla44life Jan. 8 at 6:11 PM
$VRAX Should be getting delisted from the Nasdaq soon for failing to meet listing requirements, always a good sign!
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 7 at 6:24 PM
$VRAX
0 · Reply
Urik
Urik Jan. 6 at 5:24 PM
$VRAX above 0.5 will squeeze to 1.0$ 🤞🔝
1 · Reply
ucla44life
ucla44life Jan. 5 at 4:25 PM
$VRAX SCAM GOING TO 20'S NEXT
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 5 at 3:07 PM
$VRAX
0 · Reply
Joshr1371
Joshr1371 Jan. 5 at 2:12 PM
$VRAX Price deeply depressed Trading far below prior levels & book value Shorts are crowded at low prices → vulnerable if trend flips Bearish momentum is weakening RSI ~38 = near oversold MACD negative but flattening 👉 This is often where squeezes start, not where they end.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 12:22 PM
$VRAX RSI: 38.61, MACD: -0.0365 Vol: 0.09, MA20: 0.43, MA50: 0.47 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Yung_Ball3R
Yung_Ball3R Jan. 2 at 4:37 PM
$VRAX
0 · Reply
Joshr1371
Joshr1371 Jan. 1 at 1:41 AM
$VRAX Stock re-rates significantly as the market starts attributing value to the diagnostics platform, not just cash/liabilities Price targets could stretch well above current levels based on reassessment of prospective sales curves for a unique immune profiling test Potential acquisition interest from larger diagnostics/biotech companies seeking immune profiling assets
0 · Reply
ucla44life
ucla44life Dec. 31 at 8:57 PM
$VRAX How many new suckers/bag holders were created today by one of the biggest SCAMS AND FRAUDS around? onward to 20's durrrrrrrrrrrrrrrrrr
0 · Reply
Jompa89
Jompa89 Dec. 31 at 7:11 PM
$VRAX one more push to 0.60
0 · Reply
Headon
Headon Dec. 31 at 7:00 PM
$VRAX offering..
1 · Reply